买_老虎社区_美港股上老虎

2023-01-12

买

港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈机构上调公司收入预测

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":628784077,"tweetId":"628784077","gmtCreate":1673494460499,"gmtModify":1673494462652,"author":{"id":4098320575389210,"idStr":"4098320575389210","authorId":4098320575389210,"authorIdStr":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>买</p></body></html>","htmlText":"<html><head></head><body><p>买</p></body></html>","text":"买","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/628784077","repostId":2302033490,"repostType":2,"repost":{"id":"2302033490","pubTimestamp":1673316639,"share":"https://www.laohu8.com/m/news/2302033490?lang=&edition=full","pubTime":"2023-01-10 10:10","market":"us","language":"zh","title":"港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈 机构上调公司收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2302033490","media":"智通财经","summary":"智通财经APP获悉，康宁杰瑞制药-B继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，华安证券预计，进入医保帮助恩沃利快速放量，整体降价影响较小。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。日前，康宁杰瑞制药旗下产品恩沃利首次参与医保谈判，适应症为微卫星高度不稳定晚期结直肠癌。恩沃利为全球首个皮下注射PD-L1单抗。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/09966\">康宁杰瑞制药-B</a>(09966)继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，<a href=\"https://laohu8.com/S/600909\">华安证券</a>预计，进入医保帮助恩沃利快速放量，整体降价影响较小。此前，浦银国际上调公司22E/23E/24E收入预测，主要反映恩沃利优于预期的销售成绩。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。</p><p>日前，康宁杰瑞制药旗下产品恩沃利首次参与医保谈判，适应症为微卫星高度不稳定（MSI-H）晚期结直肠癌。恩沃利为全球首个皮下注射PD-L1单抗。华安证券表示，预计进入医保帮助恩沃利快速放量，整体降价影响较小。上月，浦银国际上调公司2022E/23E/24E收入预测至2.0亿/4.5亿/5.3亿元人民币，对应63%2022-24ECAGR，主要反映恩沃利单抗优于我们预期的销售成绩。给予目标价13.6港元，维持“买入”。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈 机构上调公司收入预测</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈 机构上调公司收入预测\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-10 10:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/859503.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康宁杰瑞制药-B(09966)继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，华安证券预计，进入医保帮助恩沃利快速放量，整体降价影响较小。此前，浦银国际上调公司22E/23E/24E收入预测，主要反映恩沃利优于预期的销售成绩。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。日前，康宁杰瑞制药旗下...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/859503.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09966":"康宁杰瑞制药-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"source_url":"http://www.zhitongcaijing.com/content/detail/859503.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2302033490","content_text":"智通财经APP获悉，康宁杰瑞制药-B(09966)继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，华安证券预计，进入医保帮助恩沃利快速放量，整体降价影响较小。此前，浦银国际上调公司22E/23E/24E收入预测，主要反映恩沃利优于预期的销售成绩。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。日前，康宁杰瑞制药旗下产品恩沃利首次参与医保谈判，适应症为微卫星高度不稳定（MSI-H）晚期结直肠癌。恩沃利为全球首个皮下注射PD-L1单抗。华安证券表示，预计进入医保帮助恩沃利快速放量，整体降价影响较小。上月，浦银国际上调公司2022E/23E/24E收入预测至2.0亿/4.5亿/5.3亿元人民币，对应63%2022-24ECAGR，主要反映恩沃利单抗优于我们预期的销售成绩。给予目标价13.6港元，维持“买入”。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1677,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/628784077"}